drugset
drugset / Trial / NCT04838964

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

NCT04838964 ↗

Phase 2 Completed 15 enrolled Lepu Biopharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 as single agent in EGFR-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior standard therapy.

Timeline

Start
2021-05-18
Primary completion
2022-10-20
Completion
2022-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Becotatug Vedotin Other / unclassified 2 mg/kg Intravenous

Indications

biliary tract cancer